DXCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DexCom is a good buy for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has solid fundamental momentum, improving margins, and supportive Wall Street coverage despite some target cuts. I would buy it now rather than wait for a perfect pullback, since the current setup is constructive for a long-term entry.
DXCM is in a mixed-to-slightly bullish technical position. MACD histogram is positive and expanding, which supports near-term momentum. RSI at 52.02 is neutral, so the stock is not overbought. However, the moving-average structure is still bearish (SMA_200 > SMA_20 > SMA_5), showing the longer trend has not fully reversed yet. Price at 60.98 is above pivot 59.925 and near resistance 62.286, with support at 57.564. Short-term upside is possible, but the broader trend is still in recovery mode rather than a strong confirmed uptrend.
["Q1 2026 revenue grew 15.05% YoY to $1.192B.", "Net income rose 89.28% YoY and EPS increased 96.15% YoY, showing strong earnings acceleration.", "Gross margin improved to 62.95%, indicating better profitability.", "Management raised full-year operating margin and adjusted EBITDA margin guidance.", "Launch of the Dexcom G7 15-day CGM and Stelo platform improvements support product momentum.", "Analysts largely remain positive, with multiple Buy/Outperform ratings still in place.", "Raymond James highlighted record new user additions, strong margins, and a catalyst from type 2 diabetes reimbursement expansion."]
["Barclays remains Underweight and cited rising competition after the Q1 beat.", "Several analysts lowered price targets, showing some near-term caution.", "News flow includes a shareholder investigation by Halper Sadeh LLC, which can weigh on sentiment.", "Congress trading activity shows 2 sale transactions and no purchases in the last 90 days.", "Short-term technical trend remains mixed because the moving averages are still bearish.", "Option flow is put-heavy, suggesting cautious positioning by traders."]
DexCom’s latest reported quarter is Q1 2026. Revenue increased 15.05% YoY to $1.192B, net income increased 89.28% YoY to $199.5M, EPS rose 96.15% YoY to $0.51, and gross margin improved to 62.95%. The quarter shows strong growth in both sales and profitability, and management also raised margin guidance while maintaining full-year revenue guidance of $5.16B to $5.25B.
Wall Street remains broadly constructive, but target prices have been trimmed across several firms after Q1. Citi cut its target to $79 from $84 and kept Buy; Bernstein cut to $77 from $83 and kept Outperform; TD Cowen cut to $75 from $84 and kept Buy; Mizuho cut to $75 from $90 and kept Outperform; Baird cut to $80 from $87 and kept Outperform; Raymond James cut to $81 from $83 and kept Strong Buy; Canaccord raised its target to $100 from $95 and kept Buy; Barclays cut to $67 from $72 and kept Underweight. Overall, the pros view is still mostly bullish on fundamentals, but more cautious on near-term valuation and competition.
